Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people
- PMID: 33402392
- DOI: 10.1136/thoraxjnl-2020-216422
Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people
Abstract
Background: The association between current tobacco smoking, the risk of developing symptomatic COVID-19 and the severity of illness is an important information gap.
Methods: UK users of the Zoe COVID-19 Symptom Study app provided baseline data including demographics, anthropometrics, smoking status and medical conditions, and were asked to log their condition daily. Participants who reported that they did not feel physically normal were then asked by the app to complete a series of questions, including 14 potential COVID-19 symptoms and about hospital attendance. The main study outcome was the development of 'classic' symptoms of COVID-19 during the pandemic defined as fever, new persistent cough and breathlessness and their association with current smoking. The number of concurrent COVID-19 symptoms was used as a proxy for severity and the pattern of association between symptoms was also compared between smokers and non-smokers.
Results: Between 24 March 2020 and 23 April 2020, data were available on 2 401 982 participants, mean (SD) age 43.6 (15.1) years, 63.3% female, overall smoking prevalence 11.0%. 834 437 (35%) participants reported being unwell and entered one or more symptoms. Current smokers were more likely to report symptoms suggesting a diagnosis of COVID-19; classic symptoms adjusted OR (95% CI) 1.14 (1.10 to 1.18); >5 symptoms 1.29 (1.26 to 1.31); >10 symptoms 1.50 (1.42 to 1.58). The pattern of association between reported symptoms did not vary between smokers and non-smokers.
Interpretation: These data are consistent with people who smoke being at an increased risk of developing symptomatic COVID-19.
Keywords: clinical epidemiology; respiratory infection; tobacco and the lung; viral infection.
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: NSH is Chair of Action on Smoking and Health and Medical Director of The British Lung Foundation. TDS is a consultant to Zoe Global Ltd (Zoe), who developed the app. JW and RD are employees of Zoe Global Ltd.
Comment in
-
Citizen science in the time of COVID-19.Thorax. 2021 Jul;76(7):636-637. doi: 10.1136/thoraxjnl-2020-216673. Epub 2021 Mar 2. Thorax. 2021. PMID: 33653934 No abstract available.
Similar articles
-
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.Lancet Infect Dis. 2022 Jan;22(1):43-55. doi: 10.1016/S1473-3099(21)00460-6. Epub 2021 Sep 1. Lancet Infect Dis. 2022. PMID: 34480857 Free PMC article.
-
Influence of the SARS-CoV-2 Outbreak on the Uptake of a Popular Smoking Cessation App in UK Smokers: Interrupted Time Series Analysis.JMIR Mhealth Uhealth. 2020 Jun 11;8(6):e19494. doi: 10.2196/19494. JMIR Mhealth Uhealth. 2020. PMID: 32463375 Free PMC article.
-
A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.Trials. 2021 Jun 22;22(1):412. doi: 10.1186/s13063-021-05241-5. Trials. 2021. PMID: 34158099 Free PMC article.
-
The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).Addiction. 2021 Jun;116(6):1319-1368. doi: 10.1111/add.15276. Epub 2020 Nov 17. Addiction. 2021. PMID: 33007104 Free PMC article. Review.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Nov 17;11:CD013652. doi: 10.1002/14651858.CD013652.pub2. PMID: 32584464 Free PMC article. Updated.
Cited by
-
Variation in smoking attributable all-cause mortality across municipalities in Belgium, 2018: application of a Bayesian approach for small area estimations.BMC Public Health. 2022 Sep 7;22(1):1699. doi: 10.1186/s12889-022-14067-y. BMC Public Health. 2022. PMID: 36071426 Free PMC article.
-
Lower Gene Expression of Angiotensin Converting Enzyme 2 Receptor in Lung Tissues of Smokers with COVID-19 Pneumonia.Biomolecules. 2021 May 26;11(6):796. doi: 10.3390/biom11060796. Biomolecules. 2021. PMID: 34073591 Free PMC article.
-
Prevalence of SARS-CoV-2 infection and associated risk factors among asylum seekers living in asylum centres: A cross-sectional serologic study in Canton of Vaud, Switzerland.J Migr Health. 2023;7:100175. doi: 10.1016/j.jmh.2023.100175. Epub 2023 Mar 11. J Migr Health. 2023. PMID: 36938329 Free PMC article.
-
Can smoking prevalence explain COVID-19 indicators (cases, mortality, and recovery)? A comparative study in OECD countries.Environ Sci Pollut Res Int. 2022 Aug;29(36):55302-55310. doi: 10.1007/s11356-022-21240-8. Epub 2022 Jun 10. Environ Sci Pollut Res Int. 2022. PMID: 35688981 Free PMC article.
-
Substance, use in relation to COVID-19: A scoping review.Addict Behav. 2022 Apr;127:107213. doi: 10.1016/j.addbeh.2021.107213. Epub 2021 Dec 18. Addict Behav. 2022. PMID: 34959077 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous